Cloning and characterization of the annexin II receptor on human marrow stromal cells.

Cloning and characterization of the annexin II receptor on human marrow stromal cells. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cloning and characterization of the annexin II receptor on human marrow stromal cells. Abstract Text:

Ganwei Lu,Hidefumi Maeda,Sakamuri V Reddy,Noriyoshi Kurihara,Robin Leach,Judith L Anderson,G David Roodman,

Annexin II is a heterotetramer, consisting of two 11-kDa (p11) and two 36-kDa (p36) subunits, that is produced by osteoclasts and stimulates osteoclast formation. However, its receptor is unknown. We showed that annexin II binds to normal primary human marrow stromal cells and the Paget's marrow-derived PSV10 stromal cell line to induce osteoclast formation. 125I-Labeled annexin II binding assays with PSV10 cells demonstrated that there was a single class of annexin II receptors with a Kd of 5.79 nm and Bmax of 2.13 x 10(5) receptors/cell. Annexin III or annexin V did not bind this receptor. Using 125I-labeled annexin II binding to screen NIH3T3 transfected with a human marrow cDNA expression library, we identified a putative annexin II receptor clone, which encoded a novel 26-kDa type I membrane receptor protein when expressed in HEK 293 cells. HEK 293 cells transformed with the cloned annexin II receptor cDNA showed a similar binding affinity to annexin II as that observed in PSV10 cells. Chemical cross-linking experiments with biotinylated annexin II and intact PSV10 cells identified a 55-kDa band on Western blot analysis that reacted with both an anti-p11 antibody and streptavidin but not anti-p36 antibody. A rabbit polyclonal antibody raised against the putative recombinant annexin II receptor also recognized the same 26-kDa protein band detected in PSV10 cells. Importantly, the annexin II receptor antibody dose-dependently blocked the stimulatory effects of annexin II on human osteoclast formation, demonstrating that the receptor mediates the effects of annexin II on osteoclast formation.

Cloning and characterization of the annexin II receptor on human marrow stromal cells. Publishing Authors By Initials

G Lu,H Maeda,SV Reddy,N Kurihara,R Leach,JL Anderson,GD Roodman,

For similar cells: connective tissue cells: stromal cells research abstracts see: cells: connective tissue cells: stromal cells research

PUBMED ID PMID:

MEDLINE DATE:

Cloning and characterization of the annexin II receptor on human marrow stromal cells. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: The Journal of biological chemistry

VOLUME: 281

Page Numbers: 30542-50

Journal Abbreviation: J. Biol. Chem.

ISSN: 0021-9258

DAY: 8

MONTH: 08

YEAR: 2006

Cloning and characterization of the annexin II receptor on human marrow stromal cells. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2985121

Cloning and characterization of the annexin II receptor on human marrow stromal cells. Keywords Mesh Terms:

KEYWORDS: Stromal Cells

MESH TERMS: metabolism

Chemical & Substance for Abstract: Cloning and characterization of the annexin II receptor on human marrow stromal cells. Information

Substance Name: annexin II receptor, human

Registry Number: 0

Grant and Affiliation Information for Cloning and characterization of the annexin II receptor on human marrow stromal cells.

AFFILIATION: Medicine-Hematology/Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15240, USA.

Country: United States

AGENCY: United States NIAMS

GRANT: AR44603

ACRONYM: AR

MEDLINETA: J Biol Chem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cloning and characterization of the annexin II receptor on human marrow stromal cells Related Publications

• 1alpha,25-Dihydroxyvitamin D(3)-26,23-lactam analogues function as vitamin D receptor antagonists in human and rodent cells.
• Bone building with bortezomib.
• Cloning and characterization of the annexin II receptor on human marrow stromal cells.
• Novel approaches in the management of myeloma-related skeletal complications.
• Novel targets for myeloma bone disease.
• Paget's disease of bone: a disease of the osteoclast.
• Pathophysiology of multiple myeloma bone disease.
• Pathophysiology of myeloma bone disease.
• Perspective on the osteoclast: an angiogenic cell?
• SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma.
• Treatment strategies for bone disease.
• Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
• Ultrastructure of bone cells in Paget's disease of bone.